SunnyPharma provides independent health education for UK patients. Wegovy (semaglutide, Novo Nordisk) is a weekly GLP-1 injection licensed in the UK for chronic weight management. In June 2026, the MHRA also approved an oral Wegovy tablet — the first daily pill version of semaglutide licensed for weight management in the UK. This guide covers current prices for both the injection and the pill, how costs vary by dose and provider, NHS access, and how Wegovy compares to Mounjaro on cost and efficacy.
- Injection starting dose (0.25 mg): £99–£149/month — lowest cost phase of treatment
- Injection standard maintenance (2.4 mg): £189–£299/month — highest regular cost
- Injection higher-dose (7.2 mg): ~£250–£299/month — new MHRA-approved dose, January 2026
- Oral Wegovy pill: £99–£269/month — MHRA-approved June 2026, private only for now
- NHS cost: £9.90/prescription in England (free in Scotland, Wales, Northern Ireland) — but access is restricted to Tier 3 services
- All providers must be GPhC-registered — verify before ordering
Wegovy Injection Price by Dose — June 2026
Wegovy follows a titration schedule: you start at a low dose and increase every four weeks until reaching your maintenance dose. Because higher-dose pens contain more semaglutide, your monthly cost rises as you escalate. The table below shows typical private prescription price ranges across GPhC-registered UK pharmacies in June 2026.
| Dose | Typical use | Price range / month | Notes |
|---|---|---|---|
| 0.25 mg | Weeks 1–4 (starting dose) | £99–£149 | Lowest cost phase. Focus is tolerability, not peak weight loss. |
| 0.5 mg | Weeks 5–8 | £109–£169 | Appetite suppression begins to strengthen. |
| 1 mg | Weeks 9–12 | £129–£199 | Mid-titration. Some patients maintain at this dose. |
| 1.7 mg | Weeks 13–16 | £149–£239 | Approaching standard maintenance level. |
| 2.4 mg | Standard maintenance dose | £189–£299 | Maximum licensed standard dose. Average 14.9% weight loss over 68 weeks (STEP 1, NEJM 2021). |
| 7.2 mg | Higher-dose maintenance (new) | ~£250–£299 | MHRA-approved January 2026. Average 20.7% weight loss over 72 weeks (STEP UP). Not yet widely available from all providers. |
Sources: medino.com, comparewg.co.uk, heyslim.co.uk, igovy.co.uk (all verified June 2026). Prices are indicative ranges and change frequently. Confirm directly with each provider before ordering. All providers should be GPhC-registered.
New in 2026: the 7.2 mg Wegovy injection. The MHRA approved a higher-dose 7.2 mg semaglutide pen in January 2026 following the STEP UP trial. This dose produced average weight loss of approximately 20.7% over 72 weeks — approaching tirzepatide’s performance in SURMOUNT-1 (20.9% at 15 mg). The 7.2 mg pen is not yet widely stocked by all UK providers. Ask your prescriber whether you are eligible if you have not met your weight loss target on 2.4 mg.
What Is and Is Not Included in the Quoted Price
Wegovy requires cold-chain delivery — the pens must be refrigerated during transit. This adds a logistics cost that some providers absorb into their headline price and others charge separately. Before committing to a provider, confirm what their quoted price includes:
- Initial clinical consultation: Most online pharmacies include this. Private clinics and face-to-face services may charge £50–£150 separately for the first appointment.
- Cold-chain delivery: Wegovy must be delivered refrigerated. Some providers include this in the price; others charge £5–£15 per delivery.
- Monthly or quarterly reviews: Required for safe dose management. Many online services include brief reviews in their monthly price; others charge £30–£100 per appointment.
- Re-prescribing fees: Some providers charge a fee to reactivate a prescription if you pause treatment.
- Needle tips: Unlike Mounjaro’s KwikPen, the Wegovy pen requires needle tips for injection. Most providers include these; confirm if you are unsure.
Flat-fee vs per-pen pricing
Two pricing models exist in the UK market. Flat-fee providers charge the same monthly amount regardless of your dose — this is cheaper during the maintenance phase but may cost more at higher doses if the flat fee was set for lower doses. Per-pen providers price each dose individually — cheaper at starting doses, more expensive as you escalate. Compare both models across your likely full treatment course, not just the starting price.
New: Oral Wegovy Pill — UK Prices Since June 2026
The MHRA approved oral Wegovy (semaglutide tablet) for use in the UK in June 2026. It is the same active ingredient as the injection — semaglutide — but taken as a daily pill rather than a weekly injection. It does not require refrigeration.
Not all providers have stock yet. NHS access to the pill will require a separate NICE technology appraisal — the injection’s NICE approval (TA875, March 2023) does not automatically extend to the tablet formulation.
Wegovy vs Mounjaro — UK Price and Efficacy Comparison
Both Wegovy (semaglutide) and Mounjaro (tirzepatide) are GLP-1-based weight loss injections licensed in the UK. Wegovy is generally less expensive; Mounjaro produces greater average weight loss.
| Feature | Wegovy (semaglutide) | Mounjaro (tirzepatide) |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GIP + GLP-1 receptor agonist |
| Injection frequency | Once weekly | Once weekly |
| Standard max dose | 2.4 mg (weekly) | 15 mg (weekly) |
| Higher-dose option | 7.2 mg (MHRA Jan 2026) | Not applicable (15 mg is max) |
| Average weight loss (standard max dose, 72 wks) | 14.9% (STEP 1, NEJM 2021) | 20.9% (SURMOUNT-1, NEJM 2022) |
| Starting dose / month | ~£99–£149 | ~£119–£219 |
| Maintenance dose / month | ~£189–£299 (2.4 mg) | ~£165–£340 (10–15 mg) |
| NICE-approved (NHS) | Yes — TA875 (March 2023) | Yes — TA1026 (December 2023) |
| Oral option | Yes — MHRA approved June 2026 | No |
| Refrigeration required | Yes (injection); No (pill) | Yes |
Clinical trial data: Wilding et al. (STEP 1, NEJM 2021); Jastreboff et al. (SURMOUNT-1, NEJM 2022). Weight loss figures are averages from randomised controlled trials with lifestyle support. Individual results vary. Choice of medication should be made with your prescriber based on clinical factors, not on trial averages alone.
NHS vs Private Wegovy — What UK Patients Actually Pay
Wegovy is available on the NHS following NICE Technology Appraisal TA875 (March 2023), but access is restricted to specialist Tier 3 weight management services.
| Route | Cost to patient | Practical reality |
|---|---|---|
| NHS England | £9.90 per prescription item | Tier 3 specialist services only. BMI ≥35 (or ≥32.5 in some ethnic groups) + weight-related comorbidity + GP referral + lifestyle programme. Waiting times 12–24 months in many areas. Some NHS trusts prioritise Mounjaro over Wegovy based on local formulary. |
| NHS Scotland / Wales / Northern Ireland | Free | Same eligibility criteria and Tier 3 service requirement. Local formulary decisions vary. |
| Private prescription | £99–£299/month (injection by dose) | Available immediately from GPhC-registered pharmacies. BMI ≥30 (or ≥27 with comorbidity) for most providers. No waiting list. Full treatment course 16–20 months average; total cost approximately £2,200–£3,600. |
Getting on the NHS waiting list while paying privately
Many patients begin Wegovy privately and seek an NHS Tier 3 referral in parallel. If an NHS appointment comes through during private treatment, you can transition to NHS prescribing. This approach is clinically reasonable — discuss it with your GP. The NHS waiting list position is not affected by whether you are currently taking Wegovy privately.
How to Evaluate UK Wegovy Providers
- GPhC registration: Verify on the GPhC public register before ordering. All legitimate UK online pharmacies dispensing prescription medicines must be registered.
- Clinical assessment requirement: Any legitimate provider must require a medical questionnaire or consultation before prescribing. No clinical assessment = do not order.
- Cold-chain delivery: Wegovy injection must be delivered refrigerated. Confirm the provider uses cold-chain logistics and what they charge for it.
- Cancellation flexibility: Confirm you can pause or stop treatment without financial penalty. This matters if you experience side effects or need to change plans.
- Prescriber credentials: GMC-registered doctors or NMC-registered prescribing nurses. Confirm this is stated clearly by the provider.
The MHRA has issued warnings about counterfeit GLP-1 medications in the UK. Counterfeit Wegovy and Ozempic pens have been seized containing unknown substances. Only purchase from a GPhC-registered pharmacy that requires a clinical assessment. A price significantly below the market floor is a warning sign, not a bargain.
Related UK GLP-1 Guides
Frequently Asked Questions
Wegovy injection costs between approximately £99 and £299 per month from GPhC-registered UK pharmacies in 2026, depending on dose and provider. The 0.25 mg starting dose typically costs £99–£149; the 2.4 mg standard maintenance dose ranges from £189–£299. The new 7.2 mg higher-dose pen is priced towards the upper end of the private market. Prices were checked in June 2026 and change frequently.
Yes, Wegovy is generally less expensive. Wegovy’s starting dose typically costs £99–£149 versus £119–£219 for Mounjaro’s starting dose. At maintenance, Wegovy 2.4 mg costs approximately £189–£299 versus £165–£340 for Mounjaro 10–15 mg. However, Mounjaro produces greater average weight loss in trials — 20.9% versus 14.9% at standard maximum doses.
Oral Wegovy is a daily semaglutide tablet, MHRA-approved in the UK in June 2026. Private prices currently range from approximately £99 to £269 per month depending on dose and provider. NHS access is unlikely before 2027 as a separate NICE review is required. The pill does not require refrigeration.
Yes, but access is restricted to specialist Tier 3 weight management services following NICE TA875 (March 2023). Patients in England pay £9.90 per prescription; it is free in Scotland, Wales, and Northern Ireland. Eligibility requires BMI of 35 or above with at least one weight-related comorbidity, a GP referral, and completion of an intensive lifestyle programme. Waiting times reach 12 to 24 months in many areas.
Higher-dose pens contain more semaglutide per pen and cost more at wholesale. The titration schedule escalates from 0.25 mg to 2.4 mg over 16 to 20 weeks — so monthly cost rises as treatment progresses. Some providers charge a flat monthly fee regardless of dose; others price each pen individually.
Common additional costs include: initial consultation fee (£50–£150 if not bundled); monthly or quarterly follow-up fees (£30–£100 each if charged separately); cold-chain delivery charges (£5–£15); and re-prescribing fees if you pause treatment. A flat-fee provider may be cheaper overall than a lower headline price with per-item charges.
The MHRA approved a higher-dose 7.2 mg Wegovy injection in January 2026 following the STEP UP trial, which showed average weight loss of approximately 20.7% over 72 weeks — considerably more than the standard 2.4 mg dose (14.9%). The 7.2 mg pen is not yet available from all UK providers and is priced towards the upper end of the market.
Check the GPhC registration number at pharmacyregulation.org before ordering. All legitimate UK pharmacies dispensing prescription medicines must be GPhC-registered and must require a clinical assessment. The MHRA has warned of counterfeit GLP-1 medications in the UK — only use GPhC-verified sources.
Some UK providers offer 5–10% discounts on multi-month subscription plans. Before committing, confirm the cancellation policy. A flat-fee subscription with clear cancellation terms is generally preferable to a lower headline price with binding commitments.
Switching between GLP-1 medications requires clinical assessment — they are different molecules with different mechanisms. Discuss any switch with your prescriber. Do not change GLP-1 medications without clinical guidance.
How we reviewed this article:
SunnyPharma follows strict sourcing guidelines and relies on peer-reviewed studies, government agencies (MHRA, NICE, NHS England), manufacturer prescribing information, and verified UK provider pricing. Dr. Swiggum’s review covers the clinical content. Price data was cross-checked across GPhC-registered UK providers in June 2026. Oral Wegovy approval data sourced from MHRA announcement, June 2026. SunnyPharma does not prescribe or sell medications.
Read our editorial policy →Sources & References
- Wilding JPH et al. — STEP 1: Once-weekly semaglutide in adults with overweight or obesity. NEJM 2021;384:989–1002: nejm.org
- NICE Technology Appraisal TA875 — Semaglutide for managing overweight and obesity (March 2023): nice.org.uk
- MHRA — Wegovy (semaglutide) 7.2 mg approval (January 2026): gov.uk/mhra
- MHRA — Oral Wegovy (semaglutide tablet) UK approval (June 2026): gov.uk/mhra
- Novo Nordisk — Wegovy (semaglutide 2.4 mg) UK Summary of Product Characteristics: medicines.org.uk
- Jastreboff AM et al. — SURMOUNT-1: Tirzepatide once weekly for the treatment of obesity. NEJM 2022;387:205–216: nejm.org
- General Pharmaceutical Council — Online pharmacy register: pharmacyregulation.org
- NHS England — Tier 3 weight management services commissioning guidance: england.nhs.uk
- NHS — Treatment: Obesity: nhs.uk